Wayland Group Corp Stock Canadian Securities Exchange
Equities
CA5667241007
Pharmaceuticals
Sales 2016 | 4.06 5.56 | Sales 2017 | 3.22 4.41 | Capitalization | 203M 278M |
---|---|---|---|---|---|
Net income 2016 | -8M -10.95M | Net income 2017 | -67M -91.67M | EV / Sales 2016 * | - |
Net Debt 2016 | 9.13 12.49 | Net cash position 2017 | 0.42 0.57 | EV / Sales 2017 | 63,046,727 x |
P/E ratio 2016 * |
-
| P/E ratio 2017 |
-2.13
x | Employees | - |
Yield 2016 * |
-
| Yield 2017 |
-
| Free-Float | 100% |
Managers | Title | Age | Since |
---|---|---|---|
Ben Ward
CEO | Chief Executive Officer | 44 | - |
Dan Healey
COO | Chief Operating Officer | - | - |
Steven Bennett
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Ben Ward
CEO | Chief Executive Officer | 44 | - |
1st Jan change | Capi. | |
---|---|---|
+39.33% | 6.11B | |
-18.38% | 4.35B | |
-9.17% | 3.18B | |
+3.98% | 3.15B | |
-3.41% | 2.51B | |
+48.74% | 1.98B | |
-4.82% | 1.74B | |
-1.24% | 1.63B | |
-8.96% | 1.6B |